home / compounds / Tesamorelin / Ipamorelin blend
Tesamorelin / Ipamorelin blend
GHRH plus secretagogue stack. Components studied separately, not together.
What it is
A combination pairing a GHRH analogue with a ghrelin-receptor agonist.
What it does
The rationale is complementary stimulation of the growth-hormone axis from two directions.
Does it work?
Mechanistically coherent, but the combination itself has not been trialled. Tesamorelin’s approval data does not transfer to this blend.
Claims vs data
Each marketing claim, tagged by what the evidence actually supports.
| Mechanistically complementary GH stimulation | partially true |
| Covered by tesamorelin regulatory approval | overreach |
Reference figures
Quoted from published reference material. These are not Peptuity recommendations.
The evidence, counted
Live counts from Europe PMC and ClinicalTrials.gov.
363 publications indexed, including 38 randomised controlled trials. 21 interventional studies registered. This is a well-tested compound.
query: "Tesamorelin" · checked 2026-08-07
Most-cited literature
-
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwel · Hepatology 2023 · 1661 citations
-
An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease
Maltais F, Decramer M, Casaburi R, Barreiro E, Burelle Y, Debigaré R, · Am J Respir Crit Care Med 2014 · 693 citations
-
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors
Alexander SP, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Pete · Br J Pharmacol 2017 · 515 citations
-
G protein-coupled receptors: structure- and function-based drug discovery
Yang D, Zhou Q, Labroska V, Qin S, Darbalaei S, Wu Y, Yuliantie E, Xie · Signal Transduct Target Ther 2021 · 501 citations
Regulatory status
Formal, dated regulatory actions.
WADA — Prohibited List 2026
Blend of components that are individually prohibited in sport (WADA)
Common questions
What is the logic of this pairing?
A GHRH analogue and a ghrelin-receptor agonist stimulate growth hormone through complementary pathways — coherent mechanism, untested combination.
Does tesamorelin approval cover this blend?
No. The approval covers a specific product, dose and patient population. A compounded blend sits entirely outside it.
What would honest evidence look like here?
A trial of the combination against each component alone. Nothing of the kind exists.